Clinical and immunologic characteristics of melanoma-associated retinopathy syndrome: Eleven new cases and a review of 51 previously published cases

John L Keltner, Charles E. Thirkill, Peter T. Yip

Research output: Contribution to journalArticle

158 Citations (Scopus)

Abstract

Objective: To evaluate the signs, symptoms, and immune responses of patients with melanoma-associated retinopathy (MAR) syndrome. Materials and Methods: We reviewed the clinical and immunologic findings of 62 MAR syndrome patients. They include 25 patients from our institution (11 not previously reported) and 37 patients reported from other institutions. Results: There were 33 men and seven women (no gender information is available for the remaining 22 cases). Age at onset of the visual disturbance averaged 57.5 years (range, 30-78). Visual acuity of 20/60 or better was initially present in 82%. Fundus examination was normal in 44%, optic disc pallor was present in 23%, and retinal vessel attenuation was present in 30%. Vitreous cells were present in 30%. The latency from melanoma diagnosis to recognition of MAR syndrome averaged 3.6 years (range, 2 months to 19 years). Seven patients sustained visual improvement with various treatment regimens, especially with intravenous immunoglobulin and cytoreductive surgery (metastasectomy). Indirect immunohistochemical staining of the bipolar layer was typical, but several other retinal elements were also reactive. Tissue from a metastatic melanoma excised from one of the patients expressed antigens that reacted with antiretinal antibodies. Conclusion: MAR syndrome demonstrates diverse clinical and immunologic features. Treatment, especially intravenous immunoglobulin and cytoreductive surgery (metastasectomy), improves vision in some cases.

Original languageEnglish (US)
Pages (from-to)173-187
Number of pages15
JournalJournal of Neuro-Ophthalmology
Volume21
Issue number3
StatePublished - 2001

Fingerprint

Ocular Paraneoplastic Syndromes
Metastasectomy
Intravenous Immunoglobulins
Melanoma
Pallor
Retinal Vessels
Optic Disk
Age of Onset
Visual Acuity
Signs and Symptoms
Staining and Labeling
Antigens
Antibodies
Therapeutics

Keywords

  • Antiretinal antibodies
  • Immunology
  • Intravenous immunoglobulin treatment
  • Melanoma-associated retinopathy
  • Photopsia

ASJC Scopus subject areas

  • Clinical Neurology
  • Ophthalmology

Cite this

Clinical and immunologic characteristics of melanoma-associated retinopathy syndrome : Eleven new cases and a review of 51 previously published cases. / Keltner, John L; Thirkill, Charles E.; Yip, Peter T.

In: Journal of Neuro-Ophthalmology, Vol. 21, No. 3, 2001, p. 173-187.

Research output: Contribution to journalArticle

@article{b35d12965298463f8204c7e9423b9550,
title = "Clinical and immunologic characteristics of melanoma-associated retinopathy syndrome: Eleven new cases and a review of 51 previously published cases",
abstract = "Objective: To evaluate the signs, symptoms, and immune responses of patients with melanoma-associated retinopathy (MAR) syndrome. Materials and Methods: We reviewed the clinical and immunologic findings of 62 MAR syndrome patients. They include 25 patients from our institution (11 not previously reported) and 37 patients reported from other institutions. Results: There were 33 men and seven women (no gender information is available for the remaining 22 cases). Age at onset of the visual disturbance averaged 57.5 years (range, 30-78). Visual acuity of 20/60 or better was initially present in 82{\%}. Fundus examination was normal in 44{\%}, optic disc pallor was present in 23{\%}, and retinal vessel attenuation was present in 30{\%}. Vitreous cells were present in 30{\%}. The latency from melanoma diagnosis to recognition of MAR syndrome averaged 3.6 years (range, 2 months to 19 years). Seven patients sustained visual improvement with various treatment regimens, especially with intravenous immunoglobulin and cytoreductive surgery (metastasectomy). Indirect immunohistochemical staining of the bipolar layer was typical, but several other retinal elements were also reactive. Tissue from a metastatic melanoma excised from one of the patients expressed antigens that reacted with antiretinal antibodies. Conclusion: MAR syndrome demonstrates diverse clinical and immunologic features. Treatment, especially intravenous immunoglobulin and cytoreductive surgery (metastasectomy), improves vision in some cases.",
keywords = "Antiretinal antibodies, Immunology, Intravenous immunoglobulin treatment, Melanoma-associated retinopathy, Photopsia",
author = "Keltner, {John L} and Thirkill, {Charles E.} and Yip, {Peter T.}",
year = "2001",
language = "English (US)",
volume = "21",
pages = "173--187",
journal = "Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society",
issn = "1070-8022",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Clinical and immunologic characteristics of melanoma-associated retinopathy syndrome

T2 - Eleven new cases and a review of 51 previously published cases

AU - Keltner, John L

AU - Thirkill, Charles E.

AU - Yip, Peter T.

PY - 2001

Y1 - 2001

N2 - Objective: To evaluate the signs, symptoms, and immune responses of patients with melanoma-associated retinopathy (MAR) syndrome. Materials and Methods: We reviewed the clinical and immunologic findings of 62 MAR syndrome patients. They include 25 patients from our institution (11 not previously reported) and 37 patients reported from other institutions. Results: There were 33 men and seven women (no gender information is available for the remaining 22 cases). Age at onset of the visual disturbance averaged 57.5 years (range, 30-78). Visual acuity of 20/60 or better was initially present in 82%. Fundus examination was normal in 44%, optic disc pallor was present in 23%, and retinal vessel attenuation was present in 30%. Vitreous cells were present in 30%. The latency from melanoma diagnosis to recognition of MAR syndrome averaged 3.6 years (range, 2 months to 19 years). Seven patients sustained visual improvement with various treatment regimens, especially with intravenous immunoglobulin and cytoreductive surgery (metastasectomy). Indirect immunohistochemical staining of the bipolar layer was typical, but several other retinal elements were also reactive. Tissue from a metastatic melanoma excised from one of the patients expressed antigens that reacted with antiretinal antibodies. Conclusion: MAR syndrome demonstrates diverse clinical and immunologic features. Treatment, especially intravenous immunoglobulin and cytoreductive surgery (metastasectomy), improves vision in some cases.

AB - Objective: To evaluate the signs, symptoms, and immune responses of patients with melanoma-associated retinopathy (MAR) syndrome. Materials and Methods: We reviewed the clinical and immunologic findings of 62 MAR syndrome patients. They include 25 patients from our institution (11 not previously reported) and 37 patients reported from other institutions. Results: There were 33 men and seven women (no gender information is available for the remaining 22 cases). Age at onset of the visual disturbance averaged 57.5 years (range, 30-78). Visual acuity of 20/60 or better was initially present in 82%. Fundus examination was normal in 44%, optic disc pallor was present in 23%, and retinal vessel attenuation was present in 30%. Vitreous cells were present in 30%. The latency from melanoma diagnosis to recognition of MAR syndrome averaged 3.6 years (range, 2 months to 19 years). Seven patients sustained visual improvement with various treatment regimens, especially with intravenous immunoglobulin and cytoreductive surgery (metastasectomy). Indirect immunohistochemical staining of the bipolar layer was typical, but several other retinal elements were also reactive. Tissue from a metastatic melanoma excised from one of the patients expressed antigens that reacted with antiretinal antibodies. Conclusion: MAR syndrome demonstrates diverse clinical and immunologic features. Treatment, especially intravenous immunoglobulin and cytoreductive surgery (metastasectomy), improves vision in some cases.

KW - Antiretinal antibodies

KW - Immunology

KW - Intravenous immunoglobulin treatment

KW - Melanoma-associated retinopathy

KW - Photopsia

UR - http://www.scopus.com/inward/record.url?scp=0034748752&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034748752&partnerID=8YFLogxK

M3 - Article

C2 - 11725182

AN - SCOPUS:0034748752

VL - 21

SP - 173

EP - 187

JO - Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society

JF - Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society

SN - 1070-8022

IS - 3

ER -